Clinical trials
Recurrent or Metastatic Solid Tumors clinical trials
Below are recruiting recurrent or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,299 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06126406RecruitingPhase 1
CEA-targeting CAR-T cell therapy for advanced solid tumors
This trial tests a new immune cell therapy (CAR-T) designed to attack cancer cells that make a protein called CEA. It may be an option for people with advanced colorectal, esophageal, gastric, or pancreatic cancer who have already tried at least two standard treatments.
Wuhu, AnhuiAges 18 years+ - NCT06160596Recruiting
Understanding long-term cancer survival in hard-to-treat tumors
This study looks at why some people with hard-to-treat cancers live much longer than expected. It collects tumor samples to search for clues that might help future patients.
VillejuifAges 18 years+ - NCT06208917RecruitingPhase 3
Comparing two ways to give ondansetron for chemo nausea in kids
This trial compares two forms of ondansetron (a nausea medicine) — a dissolving film you put in the mouth versus a needle injection — to see which works better in preventing nausea and vomiting caused by chemotherapy in children with solid tumors.
Guangzhou, GuangdongAges 6 months–18 years - NCT05746897RecruitingPhase 1
First-in-human test of an anti-PVRIG drug for advanced cancers
This early-phase study tests NM1F (an anti-PVRIG antibody) in people with advanced solid tumors to see if it’s safe and whether it may work. It also includes pembrolizumab (a PD-1 “checkpoint” medicine), aiming to boost the immune system against the cancer.
Dallas, TexasAges 18 years+ - NCT06232122Recruiting
New PET scans to detect ovarian cancer recurrence
This study uses two types of PET/CT scans (68Ga-FAPI-46 and 18F-FDG) to look for any returning ovarian cancer. The goal is to find recurrence early so you and your doctor can plan the next steps.
Taoyuan CityAges 30–80 - NCT05952947RecruitingPhase 1
Study drug for HPV18-positive solid tumors with a specific immune marker
This Phase 1 trial tests HRYZ-T101 injection for people whose solid cancer is HPV18-positive and who have the HLA-DRB1*0901 immune marker. It is meant for people whose cancer has returned or spread and who have few or no effective treatment options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04810871Recruiting
Surgery for brain tumors that may come back
This study tests whether removing a brain tumor early, before it shows signs of growing back, can help prevent a recurrence. If you have had treatment before and there is still some tumor left, you may be able to join.
Rochester, MinnesotaAges 18 years+ - NCT06155396RecruitingPhase 2
Targeted drug combo for advanced cervical cancer
This trial tests a combination of two drugs: an antibody-drug conjugate (RC48-ADC) that targets HER2 on cancer cells, plus an immunotherapy (Zimberelimab) that helps your immune system attack the cancer. It is for people with advanced cervical cancer whose prior platinum-based chemotherapy has stopped working.
Bengbu, AnhuiAges 18 years+ - NCT06202261RecruitingPhase 1/Phase 2
Study of TQB2930 for breast cancer that has returned or spread
This trial tests a new drug called TQB2930 alone or with other treatments for people with recurrent or metastatic breast cancer. It may help if you have a type of breast cancer called HER2-positive and have not had many prior treatments for advanced disease.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT03659448RecruitingPhase 3
Test drug that helps map colon and rectal cancer during surgery
This Phase 3 study tests SGM-101, a drug used during surgery to help doctors better outline primary, recurrent, and spread (metastatic) colorectal cancer. It may improve how completely tumors are identified and removed during an operation.
Duarte, CaliforniaAges 18 years+ - NCT03767075RecruitingPhase 2
Basket trial matching cancer patients to targeted treatments
This trial tests whether matching your tumor’s DNA/RNA results to a specific cancer medicine can work better than standard options when cancer has spread or can’t be removed by surgery. You may be assigned to a “basket” (sub-study) based on the exact changes found in your tumor.
VillejuifAges 18 years+ - NCT06413992RecruitingPhase 2
Camrelizumab plus fluzoparib for TP53-mutated endometrial cancer
This trial tests a combination of two drugs, camrelizumab (an immunotherapy) and fluzoparib (a PARP inhibitor), for people with a specific type of endometrial cancer that has a TP53 gene mutation. It may offer a new option for advanced or recurrent disease after limited prior treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07850882Recruiting
Virus injection plus immunotherapy for advanced colorectal, stomach, or liver cancer
This study tests whether a special virus injected directly into tumors can help your body fight cancer when combined with an immunotherapy drug. It is for people with advanced colorectal, stomach, or liver cancer that has spread and who have tumors that can be reached for injection.
Guangdong, FoshanAges 18–75 - NCT06427460RecruitingPhase 2
Focused radiation therapy for solid tumors
This trial tests a special type of radiation that delivers a higher dose to the center of the tumor while limiting radiation to nearby healthy organs. It's for people with certain solid tumors that haven't spread widely or have only a few metastases.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07814248RecruitingPhase 1
TS-104 for advanced solid tumors
This trial tests a new drug called TS-104 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is given alone (not with other cancer treatments) to see if it can shrink tumors or slow their growth.
Maumee, OhioAges 18 years+ - NCT05159245RecruitingPhase 2
Targeted drug access for adults with advanced cancer
This trial helps match people with advanced, hard-to-treat cancers to targeted cancer drugs based on lab testing of their tumor. It may help if standard treatment isn’t working or isn’t available, and if your tumor has a “targetable” genetic change.
Turku, Southwest FinlandAges 18–100 - NCT07807163RecruitingPhase 2
Study of ficerafusp alfa with pembrolizumab for head and neck cancer
This study tests a new drug called ficerafusp alfa combined with pembrolizumab (an immunotherapy) in people with head and neck cancer that has returned or spread. The drug targets a protein that may help the immune system fight the cancer. The study is comparing two different schedules of giving the drug to see which is better.
Fort Myers, FloridaAges 18 years+ - NCT06508216RecruitingPhase 1/Phase 2
New drug combo for early relapsed triple-negative breast cancer
This trial tests experimental drugs for people with triple-negative breast cancer that came back within 12 months of finishing initial treatment. The goal is to see if these drugs are safe and can shrink or slow the cancer.
VillejuifAges 18 years+ - NCT06387628RecruitingPhase 2
LM-108 with immunotherapy for advanced triple-negative breast cancer
This trial tests a new drug called LM-108 combined with a PD-1 inhibitor (a type of immunotherapy) for people with triple-negative breast cancer that has come back or spread. It aims to see if this combination can help shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06534762RecruitingPhase 2
Miraberon for advanced solid tumors (first treatment)
This study tests a drug called Miraberon for people with advanced solid tumors that have not yet been treated with chemotherapy or other cancer drugs. The goal is to see if Miraberon can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–65 - NCT07775287RecruitingPhase 3
Petosemtamab plus chemotherapy for advanced colorectal cancer
This study tests a new drug called petosemtamab combined with chemotherapy for people with advanced colorectal cancer that has not responded to one prior treatment. The trial aims to see if adding petosemtamab helps the cancer shrink or grow more slowly compared to adding a standard targeted therapy like cetuximab or bevacizumab.
Los Angeles, CaliforniaAges 18 years+ - NCT06185556RecruitingPhase 2/Phase 3
New treatments for liver tumors near blood vessels or bile ducts
This trial tests two procedures—irreversible electroporation and stereotactic body radiotherapy—for people whose colorectal cancer has spread to the liver (1–3 tumors near major blood vessels or bile ducts) and can't be surgically removed or treated with heat. The goal is to see if these approaches can safely destroy those hard-to-reach tumors.
Amsterdam, North HollandAges 18 years+ - NCT06561178Recruiting
Blood Test to Monitor Esophageal Cancer After Surgery
This trial looks at whether a personalized blood test can detect cancer returning after surgery for esophageal cancer. It tests people who had chemoradiotherapy before surgery and still had some cancer remaining in the removed tissue. The goal is to use the blood test to catch any remaining or returning cancer early.
Guangzhou, GuangdongAges Any age - NCT06587425RecruitingPhase 2
Combination therapy for CLDN18.2-positive advanced stomach cancer
This study tests a combination of three drugs (LM-302, Candonilimab, and Capecitabine) as the first treatment for advanced stomach cancer that has a specific protein (Claudin 18.2). It aims to see if the combination shrinks tumors and is safe.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic solid tumors?
- Yes. Clin2 currently lists 3,299 recruiting recurrent or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.